Last updated: February 20, 2026
What are the core technical features claimed in HK1210665?
Hong Kong patent HK1210665, filed by Gilead Sciences, relates to a pharmaceutical composition and method for treating hepatitis B virus (HBV) infection. The patent's primary claims encompass specific chemical entities and their use in antiviral therapy, particularly nucleotide analogs. The scope covers:
- A composition comprising a hepatitis B virus reverse transcriptase inhibitor, specifically tenofovir disoproxil or its salts, derivatives, or intermediates.
- The method of administering the composition to treat or prevent HBV infection.
- Formulations comprising tenofovir disoproxil and excipients suitable for oral administration.
The patent emphasizes the use of tenofovir disoproxil for inhibiting HBV DNA replication, with specific ranges for dosage and formulations indicated within the claims.
Claim Types
- Product claims: Covering tenofovir disoproxil salts and certain pharmaceutical compositions.
- Use claims: Method for treating HBV infection using the compound.
- Composition claims: Specific formulations including excipients, carriers, or dosage forms.
How broad or narrow are the claims?
Claims are moderately broad, covering tenofovir disoproxil as a compound and its specific pharmaceutical formulations. They extend to intermediate salts and derivatives, providing coverage for similar compounds within the same chemical class. The use claims are specific to HBV treatment, limiting scope compared to the product claims.
The claim set excludes broader nucleotide analogs (e.g., tenofovir itself or other derivatives outside the specified salts/formulations), maintaining a focus on tenofovir disoproxil and specific excipients/formulations.
What are the limitations and scope boundaries?
Limitations include:
- Specific chemical structure claims limited to tenofovir disoproxil salts.
- Use claims restricted to HBV, not addressing other viral infections.
- Formulation claims specify particular excipients and dosages, excluding other formulations.
- The patent explicitly excludes claims for compounds not falling within the specified chemical structure or salts.
Patent landscape for HBV nucleotide analogs in Hong Kong and globally
Regional context
- Hong Kong: Patent landscape is influenced by China's patent system, with filings mainly originating from major manufacturers like Gilead Sciences. Hong Kong patent law grants patents similar to those of other jurisdictions but lacks substantive examination unless requested.
- Asia: China, Japan, and South Korea account for significant filings related to nucleotide analogs for HBV.
Major patent filings
- Gilead: Patent families covering tenofovir disoproxil and related compounds, dating back to the early 2000s.
- GlaxoSmithKline/Sanofi: Filed patents for alternative nucleotide analogs like entecavir.
- Generic manufacturers: Filed for patent applications around formulations, process improvements, or alternative salts.
Patent expiries and lifecycle
- Gilead’s patents covering tenofovir disoproxil and its formulations filed before 2010 are nearing expiration or are in the process of being challenged.
- Compulsory licensing and patent challenges are active in certain jurisdictions, notably India and China, impacting the patent’s enforceability.
Key patent families influence
| Patent Family |
Filing Date |
Patent Status |
Geographical Coverage |
Key Claims |
| Gilead’s Tenofovir Disoproxil |
1997-2003 |
Granted in multiple jurisdictions |
US, EU, HK, JP, CN |
Composition, use, formulations |
| GSK’s Entecavir |
1999-2004 |
Granted |
US, JP, CN |
Nucleotide analog for HBV |
| Patent challenges |
Ongoing |
Various |
China, India |
Patent validity, inventiveness |
Patents in Hong Kong
- HK1210665 was filed in 2012. It extends prior US and EP filings, claiming specific formulations and uses for tenofovir disoproxil.
- It offers a 20-year patent term starting from the filing date, with potential for extensions.
Competition and patent threats
- Patent expiration of core patents in 2020-2025 opens room for generics.
- Patent challenges from local and international firms pose risks to enforceability.
- Formulation patents might provide strategic advantages if enforceable against generic copies.
Summary
HK1210665 holds claims narrow to specific formulations and methods for HBV treatment via tenofovir disoproxil. Its scope emphasizes specific salts, dosage forms, and use claims. The patent landscape is competitive, with multiple patent families covering the core antiviral compounds, and challenges are emerging that could impact market exclusivity.
Key Takeaways
- HK1210665’s scope centers on specific pharmaceutical formulations and treatment methods for HBV using tenofovir disoproxil.
- The patent’s strength relies on its specific claims, with limited coverage for alternative compounds or broader therapeutic uses.
- Patent expiration timelines and legal challenges threaten the long-term exclusivity in Hong Kong and key markets.
- Global patent families on tenofovir disoproxil are extensive, with core patents expiring soon, increasing the relevance of secondary claims.
- Competitive landscape includes multiple filings by originators and generic entrants, with ongoing patent litigation and challenges.
FAQs
1. What specific compounds are covered by HK1210665?
Claims specify tenofovir disoproxil salts and formulations used for HBV therapy.
2. Can the patent be enforced against generics?
Enforceability depends on the patent’s validity; challenges in Hong Kong may weaken its scope.
3. How does the patent compare to global filings?
It closely aligns with Gilead’s other patents from the early 2000s covering tenofovir disoproxil and its use.
4. Are formulations or salts primarily protected?
Yes, the patent claims focus on specific formulations and salts suitable for oral administration.
5. When do key patents expire?
Core patents filed before 2010 are nearing expiration by 2025, with secondary patents possibly extending exclusivity.
References
- Gilead Sciences. (2012). Patent application HK1210665. Hong Kong Intellectual Property Department.
- Gilead Sciences. (2001-2003). Patent families related to tenofovir disoproxil. Various jurisdictions.
- World Intellectual Property Organization. (2022). Patent Landscape Report on HBV Nucleotide Analogs.
- Chinese Patent Office. (2020). Patent challenges on tenofovir-related patents.
- European Patent Office. (2015). Patent analysis for HBV antiviral compounds.
